Home Pharmaceutics Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

0

Centessa Pharmaceuticals plc

BOSTON and LONDON, 01 July. 10, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a research and development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver drugs effective for patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., former Senior Vice President, Global Regulatory, Security and Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors. Additionally, the company announced that Aaron Kantoff has resigned from the company’s board of directors, but will remain actively involved with the company as an advisor. Both amendments come into force on July 1, 2022.

“I am very pleased to welcome Math to the Centessa Board of Directors. Math’s deep industry experience in leading global regulatory efforts and developing new therapies will be extremely valuable as we continue to advance our rare disease and immuno-oncology pipeline of the best potential drugs for patients,” said Saurabh Saha, MD, PhD. , CEO of Centessa. “I also want to thank Aaron for his significant contributions to the Centessa Board of Directors, which have helped grow our company from its inception through our successful IPO to where we are today.”

“I am delighted to join Centessa’s Board of Directors at such a critical time for the company,” said Dr. Hukkelhoven. “I have been impressed with Centessa’s leadership team, vision and exciting portfolio, and look forward to working with the board and team to advance these potential therapies through readings from proof of concept with the ultimate goal of addressing unmet patient needs.”

Dr. Hukkelhoven is an experienced global leader in drug regulation and development. He previously served as Senior Vice President, Global Regulatory, Security and Biometrics at BMS and was also responsible for the R&D group at BMS China and the Clinical Pharmacology and Pharmacometrics group. In these roles, Dr. Hukkelhoven was responsible for establishing regulatory strategy and driving the execution of global regulatory and pharmacovigilance plans for BMS. Prior to joining BMS, Dr. Hukkelhoven served as Chairman of the Portfolio Stewardship Board at Novartis Pharmaceuticals and was Senior Vice President, Global Head Drug Regulatory Affairs at Novartis from 2001 to 2009. He also worked at Hoffmann LaRoche (Switzerland ) and Organon (The Netherlands). Dr. Hukkelhoven was chair of the PhRMA Regulatory Affairs Coordinating Committee, and most recently PhRMA negotiator for the PDUFA VII negotiations with the United States Food and Drug Administration (FDA). Dr. Hukkelhoven received his BSc and Ph.D. with honors in Biology and Biochemistry from the University of Nijmegen, The Netherlands. Dr. Hukkelhoven also sits on the board of directors of Compugen Ltd and is a senior advisor at McKinsey and an R&D strategy advisor at LianBio.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with an R&D innovation engine that aims to discover, develop and ultimately deliver effective medicines to patients. Our programs range from discovery to advanced development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a leadership team with extensive R&D experience, providing direct guidance to our program teams to rapidly progress our candidates from research through all stages of development. For more information, visit www.centessa.comwhich is not part of this version.

Forward-looking statements

This press release contains forward-looking statements. These statements can be identified by words such as “may”, “could”, “will”, “could”, “should”, “should”, “expect”, “intend”, ” plan”, “goal”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “continue”, “ongoing”, “aim”, “seek” and variations of these words or similar expressions that are intended to identify future- looking statements. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements regarding the expected benefits of the Dr. Hukkelhoven’s service on the board of directors of Centessa; statements regarding the Company’s ability to deliver effective medicines to patients; the ability of our key executives to drive the execution of the Company’s program portfolio; our asset-centric business model t the advantages and benefits expected from it; and clinical research and development plans and timing. All forward-looking statements contained in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ. significantly and unfavorably from those established. contained in or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions regarding the Company; risks inherent in the development of products and technologies; future results of our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oberland, to fund our planned clinical trials and other expenses; industry trends; the industry’s legal and regulatory framework, including obtaining and maintaining approvals to conduct or continue clinical trials; risks relating to future expenditures related to our asset-centric business model; the risk that one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in future studies; geopolitical risks such as the Russian-Ukrainian war and risks related to the ongoing COVID-19 pandemic, including the effects of Delta, Omicron and any other variants. These and other risks relating to our programs and operations are described in more detail in our Quarterly Report on Form 10-Q for the three months ended March 31, 2022, and our other reports, which are filed with the Securities and Exchange Commission. United States. We expressly disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

Kristen K. Sheppard, Esq.
SVP of Investor Relations
[email protected]